Zanubrutinib in Patients wB-Cell Lymphoma who are intolerant to Ibrutinib and/or acalabrutinib

A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Disease Types: Lymphoma

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

For More Information:

https://clinicaltrials.gov/study/NCT04116437?term=A%20Phase%202,%20Multicenter,%20Single-arm%20Study%20of%20Zanubrutinib%20(BGB-3111)%20in%20Patients%20with%20Previously%20Treated%20B-Cell%20Lymphoma%20Intolerant%20of%20Prior%20Treatment%20with%20Ibrutinib%20and%2For%20Acalabrutinib%20(BGB-3111-215)&rank=1